Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults.

摘要

AIHA is an uncommon but potentially fatal condition. It results from autoantibodies with specificity against RBC Ags leading to the premature removal of red cells from the circulation. Anemia may occur if the rate of red cell removal exceeds the ability of the BM to produce new red cells. AIHA may be secondary to drugs or underlying conditions such as CLL, infections, or autoimmune disorders. This guideline will deal specifically with idiopathic AIHA, and will not discuss secondary AIHA. Several of the treatments in this article are not licensed for the treatment of AIHA and come with little evidence, so clinicians and patients should be informed of known risks.